NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001673

Registered date:30/01/2009

Role of food intolerance and effect of protease inhibitor in patients with irritable bowel syndrome (IBS)

Basic Information

Recruitment status Complete: follow-up continuing
Health condition(s) or Problem(s) studiedIrritable bowel syndrome (IBS)
Date of first enrollment2009/02/01
Target sample size30
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Camostat mesilate 200mg (t.i.d.) will be administrated for 14 days. Rectal barostat measurements will be performed before and the end of the intervention. Placebo (t.i.d.) will be administrated for 14 days. Rectal barostat measurements will be performed before and the end of the intervention.

Outcome(s)

Primary OutcomeAdequate relief (AR) at the end of the intervention
Secondary OutcomeSymptom severity at the end of the intervention

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteriaPatients who have severe systemic/ psychological complications, and/or who have histories of any abdominal surgery except appendectomy, and/or who needs to continue any pharmacological treatment during the study

Related Information

Contact

public contact
Name Motoyori Kanazawa, MD, PhD
Address Japan
Telephone
E-mail
Affiliation Tohoku University Graduate School of Medicine Department of Behavioral Medicine
scientific contact
Name Shin Fukudo, MD, PhD
Address 2-1 Seiryo, Aoba, Sendai 980-8575, Japan Japan
Telephone
E-mail
Affiliation Tohoku University Graduate School of Medicine Department of Behavioral Medicine